Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome

Abstract

Eltrombopag is effective and safe for patients with ITP associated with SS during corticosteroid withdrawal. Thus it may be a crucial therapeutic strategy for reducing corticosteroid-related side effects in SS patients with ITP.